MBX Biosciences, Inc. Common Stock (MBX) - Total Liabilities
Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has total liabilities worth $14.95 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MBX Biosciences, Inc. Common Stock (MBX) asset resilience to evaluate the company's liquid asset resilience ratio.
MBX Biosciences, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how MBX Biosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MBX Biosciences, Inc. Common Stock total assets.
MBX Biosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Semapa
LS:SEM
|
Portugal | €3.38 Billion |
|
Jiangsu Changling Hydraulic Co. Ltd
SHG:605389
|
China | CN¥260.48 Million |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
China | CN¥2.88 Billion |
|
Suzhou Douson Drilling & Production Equipment Co Ltd
SHG:603800
|
China | CN¥1.56 Billion |
|
Deutz AG
XETRA:DEZ
|
Germany | €982.80 Million |
|
Viet Nam International Commercial Joint Stock Bank
VN:VIB
|
Vietnam | ₫533.16 Trillion |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
USA | $5.14 Million |
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
India | Rs44.37 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down MBX Biosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of MBX Biosciences, Inc. Common Stock to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MBX Biosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of MBX Biosciences, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.92 Million | +43.52% |
| 2024-12-31 | $11.09 Million | -92.92% |
| 2023-12-31 | $156.65 Million | +78.62% |
| 2022-12-31 | $87.70 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more